SAFE-HEMO-CAR-T6 Jan 2021 21:52
RNS 5th Jan 2021
" The intended outcome of the complex of activities under the Agreement is the clinical proof of concept for HEMO-CAR-T, including its variations such as SAFE-HEMO-CAR-T, for the treatment of acute myeloid leukemia ("AML")."
RNS 6th October 2020
"If these in vivo tests are successful, the Company will discuss its findings with its partners under the Sponsored Research Agreement with the University of Pennsylvania, announced on 11 August 2020, with a view to considering the inclusion of SAFE-HEMO-CAR-T in the program of pre-clinical trials currently underway there."
So, does this mean that the in vivo SAFE-HEMO-CAR-T trials were successful given that they are now included in the Penn Uni work?